Suet Nee Chen1, Orfeo Sbaizero1,2, Matthew R G Taylor1, Luisa Mestroni3. 1. Molecular Genetics, Cardiovascular Institute, University of Colorado Denver Anschutz Medical Campus, 12700 E 19th Ave #F442, Aurora, CO, 80045-2507, USA. 2. Department of Engineering and Architecture, University of Trieste (Italy), Trieste, Italy. 3. Molecular Genetics, Cardiovascular Institute, University of Colorado Denver Anschutz Medical Campus, 12700 E 19th Ave #F442, Aurora, CO, 80045-2507, USA. luisa.mestroni@ucdenver.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to provide an update on lamin A/C (LMNA)-related cardiomyopathy and discuss the current recommendations and progress in the management of this disease. LMNA-related cardiomyopathy, an inherited autosomal dominant disease, is one of the most common causes of dilated cardiomyopathy and is characterized by steady progression toward heart failure and high risks of arrhythmias and sudden cardiac death. RECENT FINDINGS: We discuss recent advances in the understanding of the molecular mechanisms of the disease including altered cell biomechanics, which may represent novel therapeutic targets to advance the current management approach, which relies on standard heart failure recommendations. Future therapeutic approaches include repurposed molecularly directed drugs, siRNA-based gene silencing, and genome editing. LMNA-related cardiomyopathy is the focus of active in vitro and in vivo research, which is expected to generate novel biomarkers and identify new therapeutic targets. LMNA-related cardiomyopathy trials are currently underway.
PURPOSE OF REVIEW: The purpose of this review is to provide an update on lamin A/C (LMNA)-related cardiomyopathy and discuss the current recommendations and progress in the management of this disease. LMNA-related cardiomyopathy, an inherited autosomal dominant disease, is one of the most common causes of dilated cardiomyopathy and is characterized by steady progression toward heart failure and high risks of arrhythmias and sudden cardiac death. RECENT FINDINGS: We discuss recent advances in the understanding of the molecular mechanisms of the disease including altered cell biomechanics, which may represent novel therapeutic targets to advance the current management approach, which relies on standard heart failure recommendations. Future therapeutic approaches include repurposed molecularly directed drugs, siRNA-based gene silencing, and genome editing. LMNA-related cardiomyopathy is the focus of active in vitro and in vivo research, which is expected to generate novel biomarkers and identify new therapeutic targets. LMNA-related cardiomyopathy trials are currently underway.
Authors: Sana M Al-Khatib; William G Stevenson; Michael J Ackerman; William J Bryant; David J Callans; Anne B Curtis; Barbara J Deal; Timm Dickfeld; Michael E Field; Gregg C Fonarow; Anne M Gillis; Christopher B Granger; Stephen C Hammill; Mark A Hlatky; José A Joglar; G Neal Kay; Daniel D Matlock; Robert J Myerburg; Richard L Page Journal: Circulation Date: 2018-09-25 Impact factor: 29.690
Authors: Antoine Bondue; Eloisa Arbustini; Anna Bianco; Michele Ciccarelli; Dana Dawson; Matteo De Rosa; Nazha Hamdani; Denise Hilfiker-Kleiner; Benjamin Meder; Adelino F Leite-Moreira; Thomas Thum; Carlo G Tocchetti; Gilda Varricchi; Jolanda Van der Velden; Roddy Walsh; Stephane Heymans Journal: Cardiovasc Res Date: 2018-08-01 Impact factor: 10.787
Authors: Satu Kärkkäinen; Tiina Heliö; Raija Miettinen; Petri Tuomainen; Paula Peltola; Juha Rummukainen; Kari Ylitalo; Maija Kaartinen; Johanna Kuusisto; Lauri Toivonen; Markku S Nieminen; Markku Laakso; Keijo Peuhkurinen Journal: Eur Heart J Date: 2004-05 Impact factor: 29.983
Authors: John M Lee; Chika Nobumori; Yiping Tu; Catherine Choi; Shao H Yang; Hea-Jin Jung; Timothy A Vickers; Frank Rigo; C Frank Bennett; Stephen G Young; Loren G Fong Journal: J Clin Invest Date: 2016-03-21 Impact factor: 14.808
Authors: Fresnida J Ramos; Steven C Chen; Michael G Garelick; Dao-Fu Dai; Chen-Yu Liao; Katherine H Schreiber; Vivian L MacKay; Elroy H An; Randy Strong; Warren C Ladiges; Peter S Rabinovitch; Matt Kaeberlein; Brian K Kennedy Journal: Sci Transl Med Date: 2012-07-25 Impact factor: 17.956
Authors: Olaya Santiago-Fernández; Fernando G Osorio; Víctor Quesada; Francisco Rodríguez; Sammy Basso; Daniel Maeso; Loïc Rolas; Anna Barkaway; Sussan Nourshargh; Alicia R Folgueras; José M P Freije; Carlos López-Otín Journal: Nat Med Date: 2019-02-18 Impact factor: 53.440
Authors: Ramin Garmany; Raquel Neves; Fatima Ali Ahmed; David J Tester; Bryan C Cannon; John R Giudicessi; Michael J Ackerman Journal: Eur Heart J Case Rep Date: 2022-03-17